Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3783_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
19 Мб
Скачать
212
https://t.me/medicina_free
R. C. Sibley and S. G. Rockson
treated with hyaluronidase demonstrated decreased swelling and improved histologic features. Additionally, the treated group demonstrated increased lymphatic vessel density and increased VEGFR3 expression. Lymphoscintigraphy dem­onstrated enhanced lymphatic drainage [25]. Pro-brotic cytokines, TGF-β and IL-4, are signicantly downregulated, whereas anti-brotic cytokines, IL-12 and IFN-γ, are upreg­ulated, resulting in suppressed brogenesis in mice treated with hyaluronidase [26]. Hyaluronidase has also been dem­onstrated to decrease lymphedema volume and reduce neu­trophils in the mouse tail model [27].
Benzopyrones
The therapeutic mechanism of benzopyrones is poorly understood. However, it has been proposed that α-benzopyrones (e.g., coumarin) activate proteolytic activ­ity of macrophages, and γ-benzopyrones (e.g., diosmin) increase oncotic pressure and the frequency and intensity of lymphatic vessel contraction. Benzopyrones are a group of drugs that have been reported to successfully treat lymph­edema, especially when combined with complete deconges­tive therapy (CDT). However, a Cochrane review found insufcient evidence to support treatment of patients with lymphedema with benzopyrones [28]. A recent prospective randomized controlled trial in BCRL demonstrated that a product containing coumarin, diosmin, and arbutin (a diuretic) combined with CDT was more effective than CDT alone in producing limb volume reduction. While hepatox­icity has been reported with coumarins in the past, this com­plication is likely dose dependent; no hepatotoxicity was identied in this study [29].
A Few Notes onNon-pharmacologic Therapies
The risk factors for lymphedema, including surgery, radia­tion, infection, and obesity, are all associated with inamma­tion and should be minimized whenever possible. Lymphedema therapists should be encouraged to use exer­cise and other physical techniques to reduce brosis. Low­level laser therapy (LLLT) demonstrates anti-inammatory and anti-brotic effects in the mouse model, and a systemic review and meta-analysis of patient with breast cancer­related lymphedema found that patients treated with LLLT, alone or in combination with other treatments, had signi­cantly decreased pain and swelling [30]. Finally, the inam­mation associated with lymphedema is decreased by CDT, and this standard of care should be optimized for all patients with lymphedema.
References
1. Avraham T, Daluvoy S, Zampell J, Yan A, Haviv YS, Rockson SG,
Mehrara BJ.Blockade of transforming growth factor-beta1 accel­erates lymphatic regeneration during wound repair. Am J Pathol. 2010;177:3202–14.
2. Tabibiazar R, Cheung L, Han J, Swanson J, Beilhack A, An A, Dadras
SS, Rockson N, Joshi S, Wagner R, Rockson SG. Inammatory manifestations of experimental lymphatic insufciency. PLoS Med. 2006;3:e254.
3. Lin S, Kim J, Lee MJ, Roche L, Yang NL, Tsao PS, Rockson
SG. Prospective transcriptomic pathway analysis of human lym­phatic vascular insufciency: identication and validation of a cir­culating biomarker panel. PLoS One. 2012;7:e52021.
4. Schneider M, Ny A, Ruiz de Almodovar C, Carmeliet P. A
new mouse model to study acquired lymphedema. PLoS Med. 2006;3:e264.
5. Hartiala P, Saarikko AM. Lymphangiogenesis and lymphangio-
genic growth factors. J Reconstr Microsurg. 2016;32:10–5.
6. Savetsky IL, Ghanta S, Gardenier JC, Torrisi JS, García Nores GD,
Hespe GE, Nitti MD, Kataru RP, Mehrara BJ.Th2 cytokines inhibit lymphangiogenesis. PLoS One. 2015;10:e0126908.
7. Shin K, Kataru RP, Park HJ, Kwon BI, Kim TW, Hong YK, Lee
SH.TH2 cells and their cytokines regulate formation and function of lymphatic vessels. Nat Commun. 2015;6:6196.
8. Nakamura K, Radhakrishnan K, Wong YM, Rockson SG. Anti-
inammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufciency in mice. PLoS One. 2009;4:e8380.
9. Zampell JC, Yan A, Elhadad S, Avraham T, Weitman E, Mehrara
BJ. CD4(+) cells regulate brosis and lymphangiogenesis in response to lymphatic uid stasis. PLoS One. 2012;7:e49940.
10. Avraham T, Zampell JC, Yan A, Elhadad S, Weitman ES, Rockson
SG, Bromberg J, Mehrara BJ. Th2 differentiation is necessary for soft tissue brosis and lymphatic dysfunction resulting from lymphedema. FASEB J. 2013;27:1114–26.
11. Gousopoulos E, Proulx ST, Bachmann SB, Scholl J, Dionyssiou
D, Demiri E, Halin C, Dieterich LC, Detmar M.Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function. JCI Insight. 2016;1:e89081.
12. Ogata F, Fujiu K, Matsumoto S, Nakayama Y, Shibata M, Oike
Y, Koshima I, Watabe T, Nagai R, Manabe I. Excess lymphan­giogenesis cooperatively induced by macrophages and CD4(+) T cells drives the pathogenesis of lymphedema. J Invest Dermatol. 2016;136:706–14.
13. Ghanta S, Cuzzone DA, Torrisi JS, Albano NJ, Joseph WJ, Savetsky
IL, Gardenier JC, Chang D, Zampell JC, Mehrara BJ.Regulation of inammation and brosis by macrophages in lymphedema. Am J Physiol Heart Circ Physiol. 2015;308:H1065–77.
14. Zampell JC, Yan A, Avraham T, Daluvoy S, Weitman ES, Mehrara
BJ.HIF-1α coordinates lymphangiogenesis during wound healing and in response to inammation. FASEB J. 2012;26:1027–39.
15. Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymph-
edema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med. 1993;329:1158–63.
16. Zampell JC, Elhadad S, Avraham T, Weitman E, Aschen S, Yan A,
Mehrara BJ. Toll-like receptor deciency worsens inammation and lymphedema after lymphatic injury. Am J Physiol Cell Physiol. 2012;302:C709–19.
17. Avraham T, Yan A, Zampell JC, Daluvoy SV, Haimovitz-Friedman
A, Cordeiro AP, Mehrara BJ.Radiation therapy causes loss of der­mal lymphatic vessels and interferes with lymphatic function by TGF-beta1-mediated tissue brosis. Am J Physiol Cell Physiol. 2010;299:C589–605.
27 New andEmerging Therapies forLymphedema: Part II
https://t.me/medicina_free
213
18. Wu M, Du Y, Liu Y, He Y, Yang C, Wang W, Gao F.Low molecular weight hyaluronan induces lymphangiogenesis through LYVE-1­mediated signaling pathways. PLoS One. 2014;9:e92857.
19. Cuzzone DA, Weitman ES, Albano NJ, Ghanta S, Savetsky IL, Gardenier JC, Joseph WJ, Torrisi JS, Bromberg JF, Olszewski WL, Rockson SG, Mehrara BJ. IL-6 regulates adipose deposition and homeostasis in lymphedema. Am J Physiol Heart Circ Physiol. 2014;306:H1426–34.
20. Jiang X, Nicolls MR, Tian W, Rockson SG.Lymphatic dysfunction, leukotrienes, and lymphedema. Annu Rev Physiol. 2018;80:49–70.
21. Rockson SG, Tian W, Jiang X, Kuznetsova T, Haddad F, Zampell J, Mehrara B, Sampson JP, Roche L, Kim J, Nicolls MR.Pilot studies demonstrate the potential benets of antiinammatory therapy in human lymphedema. JCI Insight. 2018;3:e123775.
22. Tian W, Rockson SG, Jiang X, Kim J, Begaye A, Shufe EM, Tu AB, Cribb M, Nepiyushchikh Z, Feroze AH, Zamanian RT, Dhillon GS, Voelkel NF, Peters-Golden M, Kitajewski J, Dixon JB, Nicolls MR.Leukotriene B4 antagonism ameliorates experimental lymph­edema. Sci Transl Med. 2017;9:eaal3920.
23. Gardenier JC, Kataru RP, Hespe GE, Savetsky IL, Torrisi JS, Nores GD, Jowhar DK, Nitti MD, Schoeld RC, Carlow DC, Mehrara BJ.Topical tacrolimus for the treatment of secondary lymphedema. Nat Commun. 2017;8:14345.
24. Ulivieri C, Baldari CT.Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated auto­immune diseases. Pharmacol Res. 2014;88:41–52.
25. Roh K, Cho S, Park JH, Yoo BC, Kim WK, Kim SK, Park K, Kang H, Ku JM, Yeom CH, Lee K, Lee S.Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model. Exp Biol Med (Maywood). 2017;242:584–92.
26. Cho S, Roh K, Park J, Park YS, Lee M, Cho S, Kil EJ, Cho MJ, Oh JS, Byun HS, Cho SH, Park K, Kang H, Koo J, Yeom CH, Lee S.Hydrolysis of hyaluronic acid in lymphedematous tissue allevi­ates brogenesis via TH1 cell-mediated cytokine expression. Sci Rep. 2017;7:35.
27. Jeong HJ, Roh KH, Kim GC, Kim YO, Lee JH, Lee MJ, Sim YJ.Hyaluronidase treatment of acute lymphedema in a mouse tail model. Lymphology. 2013;46:160–72.
28. Badger C, Preston N, Seers K, Mortimer P. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004:CD003140.
29. Cacchio A, Prencipe R, Bertone M, De Benedictis L, Taglieri L, D'Elia E, Centoletti C, Di Carlo G.Effectiveness and safety of a product containing diosmin, coumarin, and arbutin (Linfadren®) in addition to complex decongestive therapy on management of breast cancer-related lymphedema. Support Care Cancer. 2019;27:1471–80.
30. Smoot B, Chiavola-Larson L, Lee J, Manibusan H, Allen DD.Effect of low-level laser therapy on pain and swelling in women with breast cancer-related lymphedema: a systematic review and meta­analysis. J Cancer Surviv. 2015;9:287–304.
Lymphatic Education andResearch
https://t.me/medicina_free
Network Centers ofExcellence: AMultidisciplinary Approach toLymphatic Care
MelisaD.Grano, RosieFriedman, ArinK.Greene, andDhruvSinghal
28
The Lymphatic Education & Research Network (LE&RN) is an international nonprot organization with a mission to “ght lymphatic diseases and lymphedema through educa­tion, research and advocacy” [1]. The number of lymphatic patients is rising as the amount of cancer survivors grows, with some estimates projecting a disease burden of 7% or more of the entire US population [2]. This increase in preva­lence brings with it a surge in unmet needs of patients and increasingly overwhelmed lymphatic caretakers, as general healthcare professionals are often unfamiliar with the diag­nosis and treatment of lymphatic diseases (LD) [3]. To keep up with this demand, LE&RN established the Centers of Excellence (COE) in the Diagnosis and Treatment of Lymphatic Disease [4]. Previously, individual chapters of LE&RN were meeting patient demand by curating individ­ual ad hoc lists of lymphatic providers, collected by word of mouth [2]. However, patients struggled to determine which LD specialists could best meet their specic needs. The COE designation helps patients navigate healthcare systems by identifying pre-vetted institutions with qualied providers that are not only prepared to treat LD but also are able to con­nect patients with resources for addressing various comor­bidities. By establishing COE criteria, LE&RN crafted the blueprints for standards that institutions must meet. By mak­ing these criteria transparent, the COE designation encour­ages prospective institutions to evolve and strive for
M. D. Granoff · R. Friedman · D. Singhal (*) Boston Lymphatic Center, Division of Plastic and Reconstructive Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA e-mail: dsinghal@bidmc.harvard.edu
A. K. Greene Boston Lymphatic Center, Department of Plastic and Oral Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
excellence in lymphatic treatment, leading to optimization in care of patients [2].
A COE is a designation awarded by LE&RN to institu­tions that offer comprehensive care for lymphedema [5]. For centers that do not offer comprehensive care but do have ser­vices for patients with lymphedema, other designations can be given, including Networks of Excellence, Referral Networks of Excellence, LD Surgery COE, and LD Conservative Care COE (Fig. 28.1) [4]. These address the overall shortfall of qualied institutions for lymphedema care because some institutions offer high-quality services for the care of patients with LD, but not comprehensive care. There are 13 major categories by which LE&RN uses to evaluate applicants, each with multiple criteria, most of which must be met to achieve the COE designation. The cat­egories used to evaluate potential centers include diagnosis, imaging, nonoperative management, assessment tools, inter­ventional therapies, surgical treatments, genetics evaluation, interdisciplinary consulting ability, research, accountability, collegiality, administration, and community [4]. Once a cen­ter has applied for and been awarded a designation, their information appears on the LE&RN website, which acts as a centralized, pre-vetted, and reputable source for patients.
The Boston Lymphatic Center is an example of a LE&RN COE.We were proud to be named a COE in 2020, and we hope that by sharing our experience, other institutions might have insight into the process of applying for and attaining this designation. The foundation of our center’s approach to lymphedema care is a multidisciplinary effort. This begins with a shared vision that guides the goals of every depart­ment involved, best summarized by our mission statement: “The Boston Lymphatic Center provides compassionate care and advocacy for individuals with lymphatic disorders while uniting health care providers and researchers from all disci­plines to advance our knowledge of lymphatic disease and therapy.” Our weekly multidisciplinary conferences, which bring together nursing, diagnostic radiology, interventional radiology, nuclear medicine, vascular medicine, lymphatic
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2022 M. V. Schaverien, J. H. Dayan (eds.), Multimodal Management of Upper and Lower Extremity Lymphedema,
https://doi.org/10.1007/978-3-030-93039-4_28
215
216
https://t.me/medicina_free
M. D. Grano et al.
Fig. 28.1 Designations awarded to Lymphatic Education & Research Network (LE&RN) Centers of Excellence corresponding to the level of care
provided
surgery, physical therapy, data analytics, and research, are central to patient care. Furthermore, our principles as a cen­ter are best illustrated by our nonclinical activity. We believe sharing knowledge is critical to furthering the eld of lym­phatics and therefore began hosting the Boston Lymphatic Symposium in 2017, which runs both a patient and clinical program simultaneously. In addition, to contribute what we have learned to the medical literature, the Singhal Laboratory is a clinical and translational research group focused on elu-
cidating the role that lymphatic anatomy variations play in the development of secondary lymphedema. The Greene Laboratory is focused on identifying novel mutations for pri­mary lymphedema as well as understanding the pathophysi­ology of capillary and arteriovenous malformations that can be associated with primary lymphedema. We also believe that engagement with the community is central to furthering our goal of bringing awareness to lymphatic disease. Through collaboration with the Massachusetts chapter of LE&RN and
28 Lymphatic Education andResearch Network Centers ofExcellence: AMultidisciplinary Approach toLymphatic Care
https://t.me/medicina_free
217
their work with Governor Charlie Baker, we ofcially began celebrating World Lymphedema Day on March 6, 2018, by annually lighting the Zakim Bridge in Boston teal.
In order to simplify the experience for pediatric and adult patients, the Boston Lymphatic Center has a single toll-free call line. However, patients ultimately have slightly different courses based on whether they are an adult or pediatric patient. For adult patient care, the Boston Lymphatic Center is com­posed of a clinical triad that includes lymphatic surgery, lym­phatic medicine, and lymphatic treatment clinics (physical therapy). Upon initial evaluation by these clinics, patients are pipelined into personalized care plans based on our institu­tional algorithm, which has been previously described [6].
Patients presenting with chronic lymphedema are evalu­ated by lymphatic medicine to conrm the diagnosis and optimize medical management, by lymphatic therapy to opti­mize conservative therapies, and by imaging specialists (nuclear medicine, diagnostic radiology, interventional radi­ology) to further characterize their individual disease. The patient is then presented at the weekly multidisciplinary meeting, where the determination of whether or not they are a good surgical candidate is made. Patients with fat- dominant lymphedema are offered debulking surgery, and patients with uid-dominant lymphedema are offered a physiologic procedure, which includes vascularized lymph node transfer or lymphovenous bypass [7, 8].
Patients presenting for a risk-reducing procedure are eval­uated by the lymphatic surgery and lymphatic treatment clin­ics prior to nodal dissection to establish a baseline measure of their at-risk extremities. After undergoing oncologic sur­gery with immediate lymphatic reconstruction (ILR), they are surveilled regularly by the lymphatic treatment clinic for a minimum of 4 years. Any patients who develop lymph­edema are transferred into the chronic lymphedema arm of our center, as previously described.
In the rst year of the adult program at the Boston Lymphatic Center, nearly half of our patients were referred from outside institutions within New England, and many had bypassed other tertiary care centers in closer proximity to their home residences to seek care through our program [6]. The population consisted primarily of breast cancer patients who were seeking ILR at the time of axillary lymph node dissection for the prevention of secondary lymphedema. Fourteen percent of all patients who were referred to our pro­gram for the treatment of chronic lymphedema did not actu­ally have lymphedema and were found to have an alternative diagnosis by our lymphatic medicine team [6]. Adherence to follow-up was optimized through targeted patient outreach and coordination with other oncologic appointments. However, social determinants, nancial factors, and variable insurance coverage affected patients’ ability to present for a return visit.
Patients referred to the pediatrics arm of the Boston Lymphatic Center tend to have different presentations and medical needs than the adult program. Between 2009 and 2019, most patients referred to the center were females with congenital lymphedema [9]. Under a quarter of referred patients had secondary lymphedema, and 16% had obesity­induced lymphedema (OIL) [9]. The remainder were found to have diagnoses other than lymphedema upon evaluation, underscoring the need for greater understanding of lymph­edema by the general medical community. Upon referral, lymphedema diagnosis is similarly conrmed by lymphatic medicine as in the adult program, and individuals receive counseling and education about their condition, including ways to prevent progression and complications. All patients are initially managed by the lymphatic treatment clinic with nonoperative medical therapies such as compression gar­ments, placing focus on volume maintenance and infection prevention. In contrast to the adult pipeline, only 6% of patients in the pediatric program were treated with surgical intervention [9]. Those that were treated surgically under­went debulking surgery with suction-assisted lipectomy. Patients with OIL were referred to bariatric surgical centers, as OIL does not respond to typical lymphedema treatments, and lymphatic function cannot be improved without signi­cant weight loss. Regardless of lymphedema etiology, every patient that was referred had a tailored approach to treatment that was made possible by a collaborative effort of the multi­disciplinary team.
Summary
At the Boston Lymphatic Center, we are proud to offer com­prehensive care to patients both with and without lymph­edema and to have earned the LE&RN COE designation. We hope by sharing our experience, including the specics of our multidisciplinary approach for both children and adults, other centers may have insight into how to offer comprehen­sive care for patients with lymphatic disorders and how to secure a COE designation.
References
1. Mission | Lymphatic Education & Research Network. https://lym-
phaticnetwork.org/about/mission. Accessed 20 Feb 2021.
2. Chang D, Dayan J, Fried P, etal. Establishing standards for centers
of excellence for the diagnosis and treatment of lymphatic disease.
Lymphat Res Biol. 2021;19:4–10.
3. Rockson SG, Granger DN, Skeff KM, Chaite W.Lymphatic biology
and disease: is it being taught? Who is listening? Lymphat Res Biol.
2004;2(2):86–95.
4. Lymphatic Education & Research Network. https://lymphaticnet-
work.org/centers- of- excellence- standards. Accessed 20 Feb 2021.
218
https://t.me/medicina_free
M. D. Grano et al.
5. Lymphatic Education & Research Network. https://lymphaticnet-
work.org/centers-
6. Johnson A, Fleishman A, Tran BN, et al. Developing a lym­phatic surgery program: a rst-year review. Plast Reconstr Surg. 2019;144(6):975e–85e.
7. Granoff M, Johnson A, Shillue K, etal. A single institution multi­disciplinary approach to power-assisted liposuction for the manage­ment of lymphedema. Ann Surg. 2020.
of- excellence. Accessed 20 Feb 2021.
8. Johnson AR, Bravo MG, Granoff MD, etal. Flow-through omental ap for vascularized lymph node transfer: a novel surgical approach for delayed lymphatic reconstruction. Plast Reconstr Surg Glob Open. 2019;7(9):e2436.
9. Sudduth CL, Maclellan RA, Greene AK.Study of 700 referrals to a lymphedema program. Lymphat Res Biol. 2020;18(6):534–8.
Index
https://t.me/medicina_free
A
Activin receptor-like kinase 1 (ALK-1), 202–203 Adipose deposition, 19, 210–211 Advanced-stage lymphedema, 50 Anti-inammatory and anti-brotic therapeutic approaches, 204,
Atorvastatin, 211 Axillary lymph node dissection (ALND), 169
B
Benzopyrone immunomodulator, 44 Benzopyrones, 212 BioBridge, 207 Bioimpedance spectroscopy (BIS), 29, 32–34, 195 Bone morphogenetic protein-9 (BMP-9), 202–203 Breast cancer-related lymphedema (BCRL), 12, 30, 169, 182, 209
C
Casley-Smith methods, 41 CD4 Chronic lymphedema, 3, 71 Circaid device, 43 9-cis retinoic acid (9-cis RA), 203 Combining microvascular breast reconstruction
Complete decongestive therapy (CDT), 31, 39–44, 47, 182 Completed lymphedema function therapy (CLyFT) Protocol, 73 Complex decongestive physical therapy (CDT), 39–44 Complex lymphoedema therapy (CLT), 10 Comprehensive decongestive therapy (CDT), 10 Computed tomographic angiography (CTA), 97
211–212 ketoprofen, 204, 205 pirfenidone, 206 sodium selenite, 206 tacrolimus, 205
+
cells, 210
anatomy, 103–104 blue patent dye injections, 107 complications, 108–109 composite ap, 107 deep inferior epigastric artery perforator, 107 delayed breast reconstruction, 105 donor site closure, 108 groin vascularized lymph node ap, 107 indications, 103 operative techniques, 105–108 patient selection, 104 postoperative care, 108 preoperative assessment, 104 presurgical markings, 104–106 recipient site preparation, 108 revascularization and ap inset, 108
Controlled compression therapy (CCT), 146–148, 193 Conventional high-frequency ultrasound (CHFUS), 54–55 Coumarin, 44
D
Deep inferior epigastric artery perforator (DIEP) ap, 95, 151
E
Early-stage lymphedema, 49–50 Evidence-based algorithmic approach
advanced-stage lymphedema, 50 diagnosis and staging, 47–48 early-stage lymphedema, 49–50 broadipose soft tissue excess, 50 patient selection, 48 preclinical lymphedema, 48–49 prehabilitation, 49
F
Fibroblast growth factor-2 (FGF-2), 200 Fibro-lipo-lymph-aspiration, 78 Fibrosis and extracellular matrix, 210 Flap harvest technique, 106–108 Freiburg life quality assessment for lymphedema (FLQA-L), 36
G
Gastroepiploic lymph node ap, 159
H
Health-related quality of life (HRQoL), 175 Hepatocyte growth factor (HGF), 200 Human microvascular endothelial cells, 207 Hung-Chi Chen (HCC)-Modied Charles procedure, 160–164 Hung-Chi Chen disease, 158 Hyaluronic acid (HA), 202, 210 Hyaluronidase, 211
I
ICG lymphography, 54 Immediate lymphatic reconstruction (ILR), 1, 169, 186–187 Indocyanine green (ICG)
dye, 83 uorescent lymphography, 9, 35
imaging, 49, 152 Inducible nitric oxide synthase (iNOS), 2 Intercostobrachial cutaneous nerve, 126
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2022 M. V. Schaverien, J. H. Dayan (eds.), Multimodal Management of Upper and Lower Extremity Lymphedema,
https://doi.org/10.1007/978-3-030-93039-4
219
220
https://t.me/medicina_free
Index
Interleukin (IL)-4, 209 Interleukin-8 (IL-8), 203 Interlobular dissection, 66 “Intima-to-intima coaptation” anastomosis, 66 International Society of Lymphology (ISL) staging system, 16 Intra-abdominal VLNT
anatomy, 136 complications, 139–140 ap revascularization and inset, 138–139 operative technique, 136–138 patient selection, 136 postoperative care, 139 recipient site preparation, 138–139 small midline laparotomy incision, 137 typical indications, 135
J
Jejunal mesenteric artery, 139 Jejunal mesenteric lymph node ap, 138 JoVi Pak, 43
K
Ketoprofen, 204, 205 Klippel–Trenaunay syndrome, 31, 157
L
Lateral thoracic vascularized lymph node transfer (VLNT) ap, 154
anatomy, 123–124 complications, 127 exposing clavipectoral fascia, 125 ap inset, 126 ap inset with anastomosis, 125 ap marking, 126 marking for, 125 operative technique, 124–126 patient selection, 124 postoperative care, 126–127 reverse lymphatic mapping, 123 typical indications, 123
LDex score, 31
®
LDex
U400, 32, 195 Lesser saphenous vein (LSV), 10 Limb functional assessment instruments, 36, 196 Limb swelling, 29 Lower extremity lymphedema
anatomical changes in, 12–13 anatomophysiology of lymphatic system, 1–2 classication, 2–3 morbidity of, 3 new and emerging therapeutics, 4 pathophysiology of, 2
treatment of, 3–4 Low-stretch bandage, 41 Lymphangiogenic agents, 207 Lymphangiogenic signaling activity, 200 Lymphangiogenic therapeutic approaches, 201
ALK-1, 203
9-cis RA, 203
EPB2, 202
FGF-2 and HGF, 200
hyaluronic acid, 202
interleukin-8, 203
NRP-2, 202
S1P, 202 stem cells, 203, 204 TGF-β inhibition, 202 VEGF-C, 200
Lymphatic education & research network (LE&RN)
chronic lymphedema, 217 COE, 215 compassionate care and advocacy, 215 different presentations and medical needs, 217
treatment of lymphatic diseases, 215 Lymphatic imaging technology, 9 Lymphatic microsurgery
accessory vein with backwall sutures, 171
anatomy, 169
axillary anatomy, 170
combined procedures, 164
complications, 165, 172
excisional procedures, 160–166
fat graft, 172
front wall stitch, 171
HCC stage IV disease, 163, 164
indications, 166
intra-abdominal lymph node aps, 158–159
management of toes, 164
operative technique, 170–171
outcomes, 172
patient selection, 169–170
peripheral lymph node aps, 159
postoperative care, 171–172
therapeutic liposuction, 164
typical indications, 157–158, 169
U-stitch, 171
VLN ap, 159 LYmphatic Microsurgical Preventive Healing Approach (LYMPHA),
4, 169
Lymphatic system
anatomical changes in, 10
imaging options for the diagnosis, 7–9
lymphatic anatomy, 7
lymphatic anatomy in, 9–10
normal lymphatic anatomy, 11–12 Lymphaticovenular anastomosis (LVA), 154
anastomotic congurations, 63
CHFUS, 54, 55
complications, 67–68
detection and selection of venules, 56–57
incision site design, 60–62
indocyanine green (ICG) classication, 61
indocyanine green (ICG) staging, 61
lymphovenous shunt operations, 59
microsurgical lymphovenous anastomosis, 60
patient selection, 59–60
preoperative evaluation, 59–60
primary lower extremity lymphedema, 53
recipient vein dissection, 65
secondary lower extremity lymphedema, 53–54
severity grading of lymphosclerosis, 60
step-by-step operative techniques
careful skin closure, 66 dissection of collecting lymph vessels, 65 dissection of recipient vein, 64 exposure and incision of supercial fascia, 64–65 follow-up, 66–67 “intima-to-intima coaptation” anastomosis, 66 postoperative management, 66–67 preparation of vessels, 65
Index
https://t.me/medicina_free
221
protection of vessels and anastomosis site, 66
skin incision and retraction, 64 UEL, 54 UHFUS, 54–56
Lymphatic-venous-lymphatic plasty, 74 Lymphedema, 1, 157
adipose deposition, 19 chronic inammation, 17–19 early diagnosis of, 25 early-stage breast cancer, 23 ethology and staging of, 15–16 brosis, 17–18 implementation into practice, 25–26 inammation and brosis in, 209–211 modiable and non-modiable risk factors for, 24 pathophysiology of, 16 prospective surveillance model, 24, 25 risk factors, 23–24 staging of, 72 surgical interventions for, 187–190
Lymphedema life impact scale (LLIS), 36 Lymphedema microsurgery
combined procedures, 186 excisional procedures, 186 lymphovenous bypass procedure
prospective evaluation of, 177
retrospective cohort or comparative studies, 177–178
systematic review, 176 SAL debulking, 175
prospective/retrospective cohort/comparative studies, 184–185
systematic review of, 184 VLNT procedure
prospective cohort/comparative studies, 179–181
randomized controlled trial, 179
retrospective cohort studies, 181–184
retrospective comparative studies, 181
systematic literature review, 178, 179
Lymphedema quality of life (LYMQoL) questionnaire, 36 Lymphedema staging, 87, 157 Lymphedema surgery
degree of pitting edema, 194 detailed treatment history, 194 episodes of lymphedema, 194 L-Dex score, 195 limb functional assessment instruments, 196 limb volume measurements, 195 lymphedema-specic symptoms, 193–194 minimal clinical postoperative measurements/investigations, 194 multimodal evaluation of, 193 physiological lymphedema staging, 196 PROs, 195
Lymphedematous tissues, 210 Lymphoedema, 12 Lymphoscintigraphy, 34–35 Lymphovenous anastomosis (LVA), 157 Lymphovenous bypass (LVB), 1, 35, 47, 87, 182, 193
M
Magnetic resonance lymphangiography (MRL), 36 Manual lymphatic drainage (MLD), 7, 39, 40, 42, 73 Meige’s disease, 15 Mesenchymal stem cells (MSCs), 203 Mesoappendix, 135 Metacarpophalangeal (MCP) joint replacement surgery, 151 Microsurgical breast reconstruction (MBR), 182
Microvascular breast reconstruction (MBR), 181 Milroy’s disease, 15, 209 Moderated lymphedema, 165 Multimodal structured approach
acute-on-chronic worsening, 29 acute onset lymphedema, 29 bioimpedance spectroscopy, 32–33 clinical history, 30–31 clinical staging scales, 31–32 computed tomography/venography, 34 evidence-based evaluation, 30 extremity lymphedema symptoms, 31 ICG lymphography, 35, 36 limb measurements, 32 lymphedema physical therapy, 36–37 lymphoscintigraphy, 34–35 magnetic resonance imaging/angiography, 33–34 MRL, 36 multidisciplinary lymphedema team, 37 physical examination ndings, 31
PROMs, 36 Multiple lymphatic-venous-lymphatic anastomosis, 74 Myobroblast differentiation, 199
N
Neuropilin-2 (NRP-2), 202 Non-pharmacologic therapies, 212 Non-surgical management
CDT
compression garments, 43, 44 exercises, 42 lymphatic uid accumulation, 40 MLD, 41, 42 PCD, 42 protective clothing, 40 skin care and cellulitis risk reduction, 43 wrapping with low-stretch bandages, 40
prehabilitation, 44 Notch-1 and ephrin B2 (EPB2), 202
O
Ohio scar scale, 138 Omental VLNT
algorithm for ap harvest technique, 131
anatomy, 129–130
complications, 132
laparoscopic ap harvest technique, 131
laparoscopic visualization, 131
open ap harvest technique, 131–132
open mini-laparotomy or laparoscopic technique, 130
patient selection, 130
policeman of the abdomen, 129
postoperative care, 132
recipient site preparation, 130–131
revascularization and inset, 132
typical indications, 129
vascular anatomy of, 130 Orthotopic VLNT, 88
P
Parkes Weber syndrome, 31 Patient-reported outcome measures (PROMs), 36, 175, 195 PhotoDynamic eye, 35
222
https://t.me/medicina_free
Index
Physiological lymphedema staging, 196 Pirfenidone, 206 Pitting edema scale, 31 Pneumatic compression device (PCD), 42 Prehabilitation, 47 Primary lower extremity lymphedema (LEL), 53 Primary lymphedema, 15, 30 Prospective surveillance model (PSM), 24, 25
R
Radionucleotide lymphoscintigraphy, 196
S
Secondary lymphedema, 15, 30, 53 Secondary lymphedema risk-reduction evidence base, 24 Self-lymphatic drainage (SLD), 39 Sentinel lymph node biopsy (SLNB), 3 Single site multiple lymphatic-venous anastomosis technique
(ss-MLVA), 73, 79 anatomy, 72–73 anesthesia, 75 complications, 78 loupes and operating microscope surgical procedure, 76–77 lymph nodal-venous shunts, 71 microsurgical approach, 71 minimally invasive technique, 78 operative techniques, 75 outcomes, 78–82 patient positioning, 76 patient selection, 73–75 postoperative care, 77 preoperative and postoperative, 77–78 preoperative investigations, 73–75 recipient site preparation, 76 typical indications, 71–72
Skin paddle, 98–100 Sodium selenite (Na
SeO3), 206
2
Sphingosine-1-phosphate (S1P), 202 SPY Phi, 35 Stage-guided CLyFT Protocol, 77 Suction-assisted lipectomy (SAL) debulking, 1, 47, 176, 184–186, 193 Suction-assisted protein lipectomy (SAPL), 153
chronic lymphedema, 141–142 complications, 146, 155 controlled compression therapy, 146–148 cosmetic liposuction surgery, 153 efcacy of liposuction, 142 excess subcutaneous adiposity, 141–142 ICG mapping, 153 indications and patient selection, 152–153 ISL grade II edema, 148 liposuction of arm lymphedema, 145 magic bullet, 151 operative technique, 144 postoperative care, 146, 155 preoperative planning, 142–144 two-phase approach, 152 typical indications, 141
Supercial circumex iliac vein (SCIV), 84 Supercial inferior epigastric vein (SIEV), 84 Supermicrosurgical end-to-end (EE) anastomosis, 66 Supraclavicular vascularized lymph node transplant procedure
anatomy, 117, 118
complications, 121 distal transverse cervical vessels, 120 external jugular vein, 118 lymphovenous anastomosis, 121 omohyoid muscle, 119 operative technique, 118–120 patient selection, 117–118 postoperative care, 120–121 preoperative investigations, 117–118 presurgical markings, 118 sternocleidomastoid, 118 typical indications, 117
T
T helper (T
) 2 cytokines, 209
h
Tacrolimus, 205, 211 Tacrolimus (FK506), 206 Taiwan lymphoscintigraphy staging (TLS) system, 32, 111, 196 Total breast anatomy restoration (TBAR), 103 Transforming growth factor-beta (TGF-β), 202 Turner/Noonan syndrome, 31
U
Ubenimex, 211 Ultrahigh-frequency ultrasound (UHFUS), 55–56 Upper extremity breast cancer-related lymphedema (BCRL), 76 Upper extremity lymphedema (UEL), 54, 160
anatomical changes in, 12–13 anatomophysiology of lymphatic system, 1–2 classication, 2–3 morbidity of, 3 new and emerging therapeutics, 4 pathophysiology of, 2 treatment of, 3–4
V
Vasa lymphatica, 7 Vascular endothelial growth factor (VEGF), 199–200, 209 Vascularized lymph node transplantation (VLNT), 1, 47, 60, 117, 157,
169, 183, 193 anatomy, 96–97 anatomy of inguinal region, 96 axillary lymph node ap harvest, 84–85 “bridging” mechanism, 87 complications, 86, 100, 155 forearm of the radial vessels, 90 gravity-dependent position, 88 groin and axillary donor sites, 83 groin lymph node harvest, 85 harvesting lymph nodes, 83 indications, 84 lower leg of posterior tibial vessels, 91 mechanism of action, 95 obstructive lymphedema, 95 omental/jejunal mesenteric aps, 87 omentum and supraclavicular lymph nodes, 83 operative technique, 97–100 patient selection for, 88, 97 postoperative care, 85–86, 100, 155 postoperative management for, 91–92 “pumping” mechanism, 87 recipient site selection selection, 89–91